Key result
Carvedilol attenuated myocardial lesions, reduced virus replication, decreased MDA, and increased SOD in a murine model of viral myocarditis, whereas metoprolol and bunazosin had no significant effects.
Why the study?
Does carvedilol improve myocardial histopathological changes and inflammatory markers in a coxsackievirus B3 murine myocarditis model?
Does carvedilol improve myocardial histopathological changes and inflammatory markers in a coxsackievirus B3 murine myocarditis model?
Carvedilol provides superior protection in a murine model of viral myocarditis compared to metoprolol, likely due to its antioxidative effects and upregulation of antiinflammatory cytokines.
Answers are grounded in this paper and cite their sources.
Carvedilol shows unique effects in murine viral myocarditis; leaves open clinical translation pending human studies.
Carvedilol, a nonselective beta-blocker with additional alpha1-adrenergic blocking and antioxidant properties, has been shown to be cardioprotective in experimental myocarditis. However, the antioxidative effects of carvedilol have not been investigated in the setting of acute viral myocarditis. Therefore, this study investigated whether carvedilol protects against viral myocarditis primarily by its antioxidant and/or antiinflammatory properties. In a coxsackievirus B3 murine myocarditis model (Balb/c), effects of carvedilol and metoprolol on myocardial histopathological changes, cytokine levels, virus titers, malondialdehyde (MDA), and superoxide dismutase (SOD) contents were studied. Carvedilol markedly attenuated myocardial lesions and increased interferon-gamma and interleukin-12 production (cytokines) on day 7 with concomitant reduction of myocardial virus replication. In addition, only carvedilol decreased the content of MDA and increased the content of SOD on day 14. Metoprolol as well as bunazosin (a higly selective alpha1-adrenergic blocking agent) had no significant effects in this model. The results indicate that the superior protection of carvedilol in this model is probably the result of its antioxidative effects and the upregulation of antiinflammatory cytokines.
No takes yet. Share an insight, caveat, or question.
Li et al. (2008) studied Coxsackievirus B3-induced viral myocarditis. Carvedilol vs. Metoprolol and bunazosin was evaluated on Myocardial histopathological changes, cytokine levels, virus titers, malondialdehyde (MDA), and superoxide dismutase (SOD) contents. Carvedilol attenuated myocardial lesions, reduced virus replication, decreased MDA, and increased SOD in a murine model of viral myocarditis, whereas metoprolol and bunazosin had no significant effects.
Synapse has enriched 10 related papers. Consider them for comparative context: